{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:26:16Z","timestamp":1787109976599,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105464","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:39:15Z","timestamp":1782949155000},"page":"105464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-2120","authenticated-orcid":false,"given":"Micha\u0142","family":"Gola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart\u0142omiej Emil","family":"Krazi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kie\u017cun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Starzy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sakowicz-Burkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Godlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105464_bib1","doi-asserted-by":"crossref","first-page":"v415","DOI":"10.1093\/annonc\/mdx376.035","article-title":"1170P - Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs)","volume":"28","author":"Schrock","year":"2017","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105464_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2016.11.023","article-title":"Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro","volume":"144","author":"Bellone","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105464_bib4","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Canc Netw. 22(2D)"},{"key":"10.1016\/j.critrevonc.2026.105464_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2025.05.005","article-title":"Pragmatic preoperative molecular classification of endometrial cancers; Replacing POLE sequencing with hormone receptor staining","volume":"198","author":"Berg","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105464_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102680","article-title":"Sentinel node-positive POLE-mutated endometrial cancer","volume":"35","author":"Bogani","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105464_bib7","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib8","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/path.4185","article-title":"Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers","volume":"230","author":"Briggs","year":"2013","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105464_bib10","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/2326-6066.CIR-25-0083","article-title":"Spatiotemporal Immune Landscape and Long-term Immune Memory in POLE-Mutant Endometrial Cancer at the Single-Cell Level","volume":"13","author":"Brummel","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105464_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1596879","article-title":"Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma","volume":"15","author":"Cai","year":"2025","journal-title":"Front. Oncol."},{"issue":"7407","key":"10.1016\/j.critrevonc.2026.105464_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"issue":"7447","key":"10.1016\/j.critrevonc.2026.105464_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13073-025-01509-6","article-title":"Genome instability and crosstalk with the immune response","volume":"17","author":"Chabanon","year":"2025","journal-title":"Genome Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105464_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.critrevonc.2026.105464_bib16","article-title":"Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105464_bib17","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105464_bib18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Cremolini","year":"2026","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12920-021-01017-7","article-title":"Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing","volume":"14","author":"Davila","year":"2021","journal-title":"BMC Med. Genom."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/ijgc-2023-004864","article-title":"Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review","volume":"34","author":"De Vitis","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","article-title":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study","volume":"1","author":"Domingo","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105464_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1633260","article-title":"POLE-mutated endometrial cancer: new perspectives on the horizon?","volume":"15","author":"Fanale","year":"2025","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008572","article-title":"Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer","volume":"16","author":"Fang","year":"2020","journal-title":"PLoS. Genet."},{"key":"10.1016\/j.critrevonc.2026.105464_bib24","article-title":"Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient","volume":"13","author":"Fu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105464_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30919","article-title":"Hematopoietic stem cell transplantation in two sisters with bone marrow failure associated with POLE gene variants","volume":"71","author":"Fujimori","year":"2024","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105464_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00267","article-title":"Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers","author":"Garmezy","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105464_bib27","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.21873\/anticanres.17867","article-title":"RPA1, RFC1, and POLE Expression in Clear Cell Renal Cell Carcinoma: Immune and Clinical Relevance","volume":"45","author":"Gola","year":"2025","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.critrevonc.2026.105464_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41698-024-00592-z","article-title":"Deep learning for dual detection of microsatellite instability and POLE mutations in colorectal cancer histopathology","volume":"8","author":"Gustav","year":"2024","journal-title":"npj Precis. Onc"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.21037\/atm-20-7553","article-title":"Distinctive genomic characteristics in POLE\/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor","volume":"9","author":"He","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105464_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/iub.1276","article-title":"DNA polymerase epsilon and its roles in genome stability","volume":"66","author":"Henninger","year":"2014","journal-title":"IUBMB Life"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105464_bib31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IGC.0000000000000492","article-title":"Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma","volume":"25","author":"Hoang","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Pt 3","key":"10.1016\/j.critrevonc.2026.105464_bib32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1042\/bj3390657","article-title":"Structural organization and splice variants of the POLE1 gene encoding the catalytic subunit of human DNA polymerase e","volume":"339","author":"Huang","year":"1999","journal-title":"psilon. Biochem. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jmoldx.2025.09.008","article-title":"Preanalytical Histology Review Improves POLE Mutation Detection in Endometrial Carcinomas","volume":"28","author":"Huang","year":"2026","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2026.105464_bib34","article-title":"Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapy","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105464_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.humpath.2018.11.001","article-title":"High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma","volume":"85","author":"Ishikawa","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105464_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.963964","article-title":"Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.critrevonc.2026.105464_bib37","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/2159-8290.CD-16-0575","article-title":"Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy","volume":"6","author":"Johanns","year":"2016","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10689-025-00460-0","article-title":"Genetics, genomics and clinical features of adenomatous polyposis","volume":"24","author":"Joo","year":"2025","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105464_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1369189","article-title":"The game-changing impact of POLE mutations in oncology-a review from a gynecologic oncology perspective","volume":"14","author":"Kogl","year":"2024","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105464_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110438","article-title":"miRNA Signatures in Endometrial Cancer: Implications for Oncogenesis and Polymerase Epsilon (POLE) Mutation Status","volume":"26","author":"Lazaridis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105464_bib43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/PAS.0000000000001478","article-title":"Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification","volume":"44","author":"Leskela","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105464_bib44","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1172\/JCI122095","article-title":"Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load","volume":"128","author":"Li","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105464_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.70040","article-title":"Synchronous endometrial\/cervical and ovarian\/fallopian tube carcinoma: a genome-wide mutation analysis","volume":"11","author":"Li","year":"2025","journal-title":"J. Pathol. Clin. Res."},{"issue":"1151","key":"10.1016\/j.critrevonc.2026.105464_bib46","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20221063","article-title":"Multisequence MRI-based radiomics model for predicting POLE mutation status in patients with endometrial cancer","volume":"96","author":"Lin","year":"2023","journal-title":"Br. J. Radiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12943-018-0832-y","article-title":"Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105464_bib48","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ajhg.2018.10.024","article-title":"DNA Polymerase Epsilon Deficiency Causes IMAGe Syndrome with Variable Immunodeficiency","volume":"103","author":"Logan","year":"2018","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","article-title":"POLE\/POLD1 mutation and tumor immunotherapy","volume":"41","author":"Ma","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105464_bib50","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41588-022-01108-w","article-title":"Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity","volume":"54","author":"Ma","year":"2022","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105464_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012190","article-title":"Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants","volume":"13","author":"Maddalena","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105464_bib52","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105464_bib53","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105464_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233066","article-title":"High polymerase epsilon expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer","volume":"15","author":"Min","year":"2020","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105464_bib55","article-title":"Characterization of POLE-mutated (POLE+) urothelial carcinoma of the bladder and urinary tract (UC)","author":"MinYuen Teo","year":"2017","journal-title":"Meet. Abstr. 2017 Genitourin. Cancers Symp."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000881","article-title":"Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer","volume":"8","author":"Mo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105464_bib57","article-title":"Upregulated long non-coding RNAs TMPO-AS1, DDX11-AS1, and POLE gene expression predict poor prognosis in head and neck squamous cell carcinoma (HNSCC)","volume":"36","author":"Mokhtarinejad","year":"2024","journal-title":"Gene Rep."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105464_bib58","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1038\/s41436-020-0922-2","article-title":"Role of POLE and POLD1 in familial cancer","volume":"22","author":"Mur","year":"2020","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13073-023-01234-y","article-title":"Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1","volume":"15","author":"Mur","year":"2023","journal-title":"Genome Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35731","article-title":"POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center cohort","volume":"131","author":"Nero","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113655","article-title":"DNA polymerase epsilon and delta variants drive mutagenesis in polypurine tracts in human tumors","volume":"43","author":"Ostroverkhova","year":"2024","journal-title":"Cell. Rep."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105464_bib62","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1084\/jem.20121303","article-title":"Polymerase epsilon1 mutation in a human syndrome with facial dysmorphism, immunodeficiency, livedo, and short stature (\"FILS syndrome\"","volume":"209","author":"Pachlopnik Schmid","year":"2012","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ng.2503","article-title":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","volume":"45","author":"Palles","year":"2013","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib64","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10689-021-00256-y","article-title":"The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management","volume":"21","author":"Palles","year":"2022","journal-title":"Fam. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105464_bib65","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(25)00379-1","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial","volume":"26","author":"Post","year":"2025","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105464_bib66","article-title":"Prognostic value of tertiary lymphoid structures in molecular subgroups of endometrial carcinoma","volume":"35","author":"Pradhan","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105464_bib67","article-title":"Tumor mutation burden in colorectal cancers with POLE exonuclease and non-exonuclease domain variants","volume":"41","author":"Ringenbach","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105464_bib68","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","article-title":"PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon","volume":"12","author":"Rousseau","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib69","doi-asserted-by":"crossref","DOI":"10.3171\/2021.11.FOCUS21592","article-title":"Association of mutations in DNA polymerase epsilon with increased CD8+ cell infiltration and prolonged progression-free survival in patients with meningiomas","volume":"52","author":"Rutland","year":"2022","journal-title":"Neurosurg. Focus."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105464_bib70","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1158\/1078-0432.CCR-16-1031","article-title":"Regression of Chemotherapy-Resistant Polymerase epsilon (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab","volume":"22","author":"Santin","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105464_bib71","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","article-title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","volume":"30","author":"Schrock","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib72","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/mutage\/gez027","article-title":"The missing heritability of familial colorectal cancer","volume":"35","author":"Schubert","year":"2020","journal-title":"Mutagenesis"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/2767-9764.CRC-23-0312","article-title":"Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity","volume":"4","author":"Shah","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105464_bib74","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1530\/EC-20-0258","article-title":"POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer","volume":"9","author":"Siraj","year":"2020","journal-title":"Endocr. Connect."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105464_bib75","article-title":"POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East","volume":"8","author":"Siraj","year":"2020","journal-title":"Mol. Genet. Genom. Med."},{"key":"10.1016\/j.critrevonc.2026.105464_bib76","doi-asserted-by":"crossref","unstructured":"Sher, E.F., Fujihara, K.M., Tao, A., Sastourne-Haletou, P., Erenburg, D., Sviderskiy, V.O., Mir, H., Karakousi, T., Loomis, C.A., Deng, J., Ruggles, K.V., Wong, K.K., Possemato, R., 2026. Targeting DNA Polymerase Epsilon Induces Tumor Clearance and Activates an NF-\u03baB-Mediated Inflammatory Response in Triple Negative Breast Cancer. Cancer Res. Epub ahead of print.","DOI":"10.1158\/0008-5472.c.8596088"},{"key":"10.1016\/j.critrevonc.2026.105464_bib77","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12935-019-1058-9","article-title":"Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region","volume":"19","author":"Siraj","year":"2019","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.critrevonc.2026.105464_bib78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2018.02.004","article-title":"Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer","volume":"118","author":"Song","year":"2018","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib79","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad033","article-title":"Replication DNA polymerases, genome instability and cancer therapies","volume":"5","author":"Strauss","year":"2023","journal-title":"NAR Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105464_bib80","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.molcel.2020.10.016","article-title":"Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase e","volume":"80","author":"Sviderskiy","year":"2020","journal-title":"psilon. Mol. Cell."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib81","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/jmg-2023-109444","article-title":"Congenital anaemia associated with loss-of-function variants in DNA polymerase epsilon 1","volume":"61","author":"Takeuchi","year":"2024","journal-title":"J. Med. Genet."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105464_bib82","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.7150\/jca.64765","article-title":"Increased DNA Polymerase Epsilon Catalytic Subunit Expression Predicts Tumor Progression and Modulates Tumor Microenvironment of Hepatocellular Carcinoma","volume":"13","author":"Tang","year":"2022","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41419-023-06418-3","article-title":"The P286R mutation of DNA polymerase epsilon activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway","volume":"15","author":"Tang","year":"2024","journal-title":"Cell. Death Dis."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib84","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.5081","article-title":"Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response","volume":"245","author":"Temko","year":"2018","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105464_bib85","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00404-020-05531-4","article-title":"TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma","volume":"301","author":"Travaglino","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105464_bib86","article-title":"Potential impact of non-exonuclease POLE and POLD1 mutations on high and ultrahigh TMB across cancers","volume":"43","author":"Tsai","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105464_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104436","article-title":"POLARIX: POLE-mutation analysis by rapid image-based screening in endometrial cancer","volume":"36","author":"van den Berg","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105464_bib88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(25)00612-6","article-title":"Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial","volume":"27","author":"van den Heerik","year":"2026","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105464_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100843","article-title":"Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications","volume":"38","author":"Viana-Errasti","year":"2025","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105464_bib90","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/curroncol29030117","article-title":"Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies","volume":"29","author":"Voutsadakis","year":"2022","journal-title":"Curr. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105464_bib91","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105464_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107439","article-title":"Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer","volume":"187","author":"Wang","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105464_bib93","article-title":"Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib94","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40478-023-01689-5","article-title":"Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases epsilon and delta in glioma families","volume":"11","author":"Weber","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.critrevonc.2026.105464_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.751977","article-title":"Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105464_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061467","article-title":"Polymerase Epsilon-Associated Ultramutagenesis in Cancer","volume":"14","author":"Xing","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib97","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12916-025-04611-z","article-title":"The clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome","volume":"24","author":"Xu","year":"2026","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105464_bib98","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000538288","article-title":"Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?","volume":"68","author":"Yanazume","year":"2024","journal-title":"Acta Cytol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105464_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52414-z","article-title":"Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population","volume":"9","author":"Yao","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105464_bib100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/CMAR.S445055","article-title":"The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive Review","volume":"16","author":"Yao","year":"2024","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2026.105464_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.946881","article-title":"Clinical characteristics and gene mutation profiles of chronic obstructive pulmonary disease in non-small cell lung cancer","volume":"12","author":"Yuan","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105464_bib102","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/oncolo\/oyac027","article-title":"Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer","volume":"27","author":"Zhang","year":"2022","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105464_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002356","article-title":"Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105464_bib104","article-title":"POLE Deficiency Exacerbates Diesel Engine Exhaust-Induced Genomic Instability and Malignant Transformation of Bronchial Epithelial Cells","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105464_bib105","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1111\/1759-7714.15012","article-title":"Integrating POLE\/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Thorac. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105464_bib106","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ccell.2023.09.006","article-title":"Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden","volume":"41","author":"Zhu","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105464_bib107","first-page":"49","article-title":"Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma","volume":"761","author":"Zou","year":"2014","journal-title":"Mutat. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:41:59Z","timestamp":1787107319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":107,"alternative-id":["S1040842826003513"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105464","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105464"}}